Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC by Heymach, J, Hanrahan, E, Mann, H, Langmuir, P, Natale, R, Johnson, B, Herbst, R, Ryan, A

Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. by Hanrahan, E, Ryan, A, Mann, H, Kennedy, S, Langmuir, P, Natale, R, Herbst, R, Johnson, B, Heymach, J

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. by Hanrahan, E, Lin, H, Kim, E, Yan, S, Du, D, McKee, K, Tran, H, Lee, J, Ryan, A, Langmuir, P, Johnson, B, Heymach, J

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. by Wells, SA, Robinson, BG, Gagel, R, Dralle, H, Fagin, J, Santoro, M, Baudin, E, Elisei, R, Jarzab, B, Vasselli, JR, Read, J, Langmuir, P, Ryan, A, Schlumberger, M

Treatment of Metastatic Medullary Thyroid Cancer With Vandetanib: Need to Stratify Patients on Basis of Calcitonin Doubling Time Reply by Jr, W, Robinson, BG, Gagel, R, Dralle, H, Fagin, J, Santoro, M, Baudin, E, Elisei, R, Jarzab, B, Vasselli, JR, Read, J, Langmuir, P, Ryan, A, Schlumberger, M

Reply to J.-F. Chatal et al. by Wells Jr, SA, Robinson, BG, Gagel, R, Dralle, H, Fagin, J, Santoro, M, Baudin, E, Elisei, R, Jarzab, B, Vasselli, JR, Read, J, Langmuir, P, Ryan, A, Schlumberger, M